ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

About this update from Endra Life Sciences Inc.

[{"type":"text","content":"Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"ANN ARBOR, Mich., March 31, 2025--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies.","length":462,"tagName":"p"},{"type":"text","content":"ENDRA’s management has thoroughly evaluated the Company’s technical capabilities and go-to-market strategy for TAEUS Liver and determined that this new target market opportunity is far larger and more viable than its prior focus on hepatology and radiology markets, noting that metabolic diseases are an upstream phenomenon that lead to multiple risk factors including those specific to liver diseases. With this pivot toward metabolic health, ENDRA’s revised mission is to develop and market an accurate, simple-to-use, inexpensive, point-of-care test – essentially a "blood pressure cuff" – for the assessment and management of steatotic liver disease (SLD).","length":670,"tagName":"p"},{"type":"text","content":""SLD is on the rise and represents an enormous health burden that affects over two billion people globally and approximately one-third of the U.S. population. As GLP-1 therapies continue to be embraced to treat metabolic risk factors such as obesity, type 2 diabetes and cardiovascular disease, there is an unmet need for a cost-effective, simple-to-use and accurate point-of-care test," said Alexander Tokman, Chief Executive Officer of ENDRA. "We believe our TAEUS technology is uniquely positioned to fill this gap and meet the needs of providers, patients and payers. Our development efforts are now focused on refining TAEUS’ design for this use as we continue to collect crucial clinical data to support our future De Novo regulatory filing with the FDA."","length":781,"tagName":"p"},{"type":"text","content":"Highlights of this strategy include new target customer segments, ...

More updates from Endra Life Sciences Inc.